Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Improving the detection of progression in longitudinal microperimetry data in age-related macular degeneration by using pointwise analysis of data - a MACUSTAR study report
Author Affiliations & Notes
  • Jeremy TAN
    Optometry and Visual Sciences, City University of London, London, London, United Kingdom
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Giovanni Montesano
    Optometry and Visual Sciences, City University of London, London, London, United Kingdom
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Charlotte Behning
    Institute of Medical Biometry, Informatics and Epidemiology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Hannah M P Dunbar
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
    Visual Neuroscience, University College London, London, United Kingdom
  • Robert Finger
    Department of Ophthalmology, Universitat Heidelberg, Mannheim, Baden-Württemberg, Germany
  • Jan Henrik Terheyden
    Optometry and Visual Sciences, City University of London, London, London, United Kingdom
    Department of Ophthalmology, Universitatsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Stephen H Poor
    Novartis AG, Basel, Basel-Stadt, Switzerland
  • Sergio Leal
    Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Adnan Tufail
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
    University College London, London, United Kingdom
  • Frank G Holz
    Department of Ophthalmology, Universitatsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Ulrich F O Luhmann
    F Hoffmann-La Roche AG Research and Development Division, Basel, Basel-Stadt, Switzerland
  • David P. Crabb
    Optometry and Visual Sciences, City University of London, London, London, United Kingdom
  • Footnotes
    Commercial Relationships   Jeremy TAN None; Giovanni Montesano Alcon, CenterVue-iCare, Omikron, Code C (Consultant/Contractor), :Relayer, LtD, Code O (Owner), Alcon;, Code R (Recipient); Charlotte Behning None; Hannah Dunbar Boehringer Ingelheim, Code C (Consultant/Contractor), Apellis, Code R (Recipient); Robert Finger Alimera, Apellis, Bayer, Böhringer-Ingelheim, Novartis, ODOS, Oxford Innovation, ProGenerika, Roche/Genentech, Code C (Consultant/Contractor), Biogen, CentreVue, Heidelberg Engineering, Zeiss Meditec, Code F (Financial Support); Jan Terheyden Carl Zeiss MedicTec, CenterVue, Heidelberg Engineering, Optos, Code F (Financial Support), Novartis, Okko, Code R (Recipient); Stephen Poor Novartis Pharmaceuticals, Corporation, Code E (Employment); Sergio Leal BAYER AG, Code E (Employment); Adnan Tufail Apellis, Bayer, Böhringer-Ingelheim, Roche/Genetech, Iveric Bio, Janssen, Oxurion, Thea, Code C (Consultant/Contractor), Heidelberg Engineering, Novartis, Allergan, Code S (non-remunerative); Frank Holz Acucela, Alexion, Alzheon, Apellis, Astellas, Bayer, Boehringer-Ingelheim, Bioeq/Formycon, Roche/Genentech, Graybug, Gyroscope, Allergan, Heidelberg Engineering, IvericBio, Janssen, Kanghong, LinBioscience, Novartis, Pixium Vision, Oxurion, Stealth BioTherapeutics, Zeiss., Code C (Consultant/Contractor), Bayer, Bioeq/Formycon, CenterVue, Geuder, Allergan, Heidelberg Engineering, IvericBio, Kanghong, NightStarX, Novarti, Optos, Pixium Vision, Zeiss., Code F (Financial Support), GRADE Reading Center, Code O (Owner); Ulrich Luhmann F. Hoffmann-La Roche Ltd. , Code E (Employment), F. Hoffmann-La Roche Ltd. , Code I (Personal Financial Interest); David Crabb AbbVie/Allergan, Apellis, Janssen. , Code C (Consultant/Contractor), AbbVie/Allergan, Apellis, Santen. , Code F (Financial Support), AbbVie/Allergan, Sante, Thea, Glaukos, Code R (Recipient)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5686. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jeremy TAN, Giovanni Montesano, Charlotte Behning, Hannah M P Dunbar, Robert Finger, Jan Henrik Terheyden, Stephen H Poor, Sergio Leal, Adnan Tufail, Frank G Holz, Ulrich F O Luhmann, David P. Crabb; Improving the detection of progression in longitudinal microperimetry data in age-related macular degeneration by using pointwise analysis of data - a MACUSTAR study report. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5686.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Single summary (global) measures from microperimetry are commonly used to monitor visual function in trials for age-related macular degeneration (AMD). We evaluate the performance of pointwise (location) analyses in detecting functional progression in intermediate AMD in the MACUSTAR prospective study.

Methods : We used mesopic microperimetry data (MAIA; iCARE, Finland) from 447 study participants with intermediate AMD (Beckman classification by a central reading center) from 20 sites across Europe. Microperimetry (33-point test pattern) was performed at 9 visits over a median of 3 years (IQR 1.5-3.5). We used structural conversion to late AMD observed in 80 participants as the independent reference standard for progression in this study. Two index methods of detecting progression were evaluated: [1] Ordinary rate of change in global mean sensitivity. [2] Trend-based pointwise progression using linear mixed-effects models used in data from standard perimetry in glaucoma. We estimated mean time to detection of progression and proportion of progressors detected (hit-rate) at the same specificity (1 – false positive rate), derived by applying the same methods to random permutations of the test series of 367 eyes which did not demonstrate structural conversion.

Results : There was a greater rate of sensitivity loss in microperimetry measurement in eyes that demonstrated structural conversion compared to those that did not (global mean sensitivity -1.17 (2.5%/97.5% confidence intervals = -0.85/-1.47) vs -0.37 (0.28/-0.46) dB/year, p < 0.0001). Mean time to detection of progression was consistently lower in the pointwise method with a mostly equivalent hit-rate (Figure 1); for example, at a 5% false positive rate the time to progression was 2.76 and 3.09 years for pointwise and global mean sensitivity methods respectively. The pointwise method also had a 2.8 times (CI 1.6/4.3) higher likelihood of detecting progression compared to the global mean sensitivity method (p < 0.0001, Figure 2).

Conclusions : In the analysis of longitudinal microperimetry data, a trend-based pointwise method is quicker at detecting progression compared to using global sensitivity change. The relative gains would likely translate to greater power for trials (shorter duration or fewer participants) where microperimetry is used as a functional endpoint.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×